ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives to long-standing standards of care that include low-molecular-weight heparin and warfarin. The development of apixaban reflects a strategy to optimize the clinical pharmacology profile, dosing posology, tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Michael S, Mohan, Puneet, Knabb, Robert, Gupta, Elora, Frost, Charles, Lawrence, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Pharmaceutical Science to Improve the Human Condition: Prix Galien 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260137/
https://www.ncbi.nlm.nih.gov/pubmed/25377080
http://dx.doi.org/10.1111/nyas.12567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260137/
https://www.ncbi.nlm.nih.gov/pubmed/25377080
http://dx.doi.org/10.1111/nyas.12567

Ejemplares similares